Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Butler John P.CEO and President | Akebia TherapeuticsAKBA | Open-market buy | 03/04 | 03/05 | 69,270 sh | $1.25 | $86,587.5 | +2.1% |
Akebia TherapeuticsAKBA | Open-market sale10b5-1 plan | 02/02 | 02/04 | 341,305 sh4 trades | $1.39avg. | $474,413.95 | −9.4% | |
Akebia TherapeuticsAKBA | Open-market sale10b5-1 plan | 02/02 | 02/04 | 67,658 sh3 trades | $1.39avg. | $94,044.62 | −6.7% | |
Akebia TherapeuticsAKBA | Open-market sale10b5-1 plan | 02/02 | 02/04 | 84,829 sh2 trades | $1.39avg. | $117,912.31 | −13.1% | |
Erik OstrowskiSVP, CFO, CBO & Treasurer | Akebia TherapeuticsAKBA | Open-market sale10b5-1 plan | 02/02 | 02/04 | 34,951 sh | $1.39 | $48,581.89 | −4.9% |
Akebia TherapeuticsAKBA | Open-market sale10b5-1 plan | 02/02 | 02/04 | 49,524 sh2 trades | $1.39avg. | $68,838.36 | −14.2% | |
Akebia TherapeuticsAKBA | Open-market sale10b5-1 plan | 02/02 | 02/04 | 69,772 sh3 trades | $1.39avg. | $96,983.08 | −10.6% | |
Erik OstrowskiSVP, CFO, CBO & Treasurer | Akebia TherapeuticsAKBA | Open-market sale10b5-1 plan | 25/06/30 | 25/07/01 | 41,314 sh | $3.67 | $151,622.38 | −7.6% |
Richard C. MalabreSVP, Chief Accounting Officer | Akebia TherapeuticsAKBA | Open-market sale10b5-1 plan | 25/06/09 | 25/06/11 | 15,000 sh | $4.01 | $60,150 | −5.3% |
Richard C. MalabreSVP, Chief Accounting Officer | Akebia TherapeuticsAKBA | Open-market sale10b5-1 plan | 25/06/04 | 25/06/05 | 13,334 sh | $3.53 | $47,069.02 | −4.8% |
Butler John P.CEO and President | Akebia TherapeuticsAKBA | Open-market sale10b5-1 plan | 25/03/03 | 25/03/04 | 46,409 sh | $1.83 | $84,928.47 | −1.8% |
Burke Steven KeithSVP, Chief Medical Officer | Akebia TherapeuticsAKBA | Open-market sale10b5-1 plan | 25/03/03 | 25/03/04 | 7,144 sh | $1.83 | $13,073.52 | −0.9% |
Akebia TherapeuticsAKBA | Open-market sale10b5-1 plan | 25/02/03 | 25/02/04 | 144,250 sh2 trades | $2.10avg. | $302,925 | −5.2% | |
Akebia TherapeuticsAKBA | Open-market sale10b5-1 plan | 25/02/03 | 25/02/04 | 50,506 sh2 trades | $2.10avg. | $106,062.6 | −5.8% | |
Grund NicholasChief Commercial Officer | Akebia TherapeuticsAKBA | Open-market sale10b5-1 plan | 25/02/03 | 25/02/04 | 55,621 sh | $2.10 | $116,804.1 | −11.2% |
Richard C. MalabreSVP, Chief Accounting Officer | Akebia TherapeuticsAKBA | Open-market sale10b5-1 plan | 25/02/03 | 25/02/04 | 30,202 sh | $2.10 | $63,424.2 | −9.7% |
Nicole R. HadasSVP, Chief Legal Officer | Akebia TherapeuticsAKBA | Open-market sale10b5-1 plan | 24/05/13 | 24/05/14 | 12,016 sh | $1.26 | $15,140.16 | −1.8% |
Michel DahanSVP, COO | Akebia TherapeuticsAKBA | Open-market sale10b5-1 plan | 24/05/13 | 24/05/14 | 34,840 sh | $1.26 | $43,898.4 | −4.9% |
Burke Steven KeithSVP, Chief Medical Officer | Akebia TherapeuticsAKBA | Open-market sale | 23/08/25 | 24/05/09 | 27,000 sh | $1.15 | $31,050 | −3.9% |
Butler John P.CEO and President | Akebia TherapeuticsAKBA | Open-market sale | 24/02/29 | 24/03/01 | 46,570 sh | $1.58 | $73,580.6 | −2.2% |